SlideShare ist ein Scribd-Unternehmen logo
1 von 5
Downloaden Sie, um offline zu lesen
Single-Use
  Bioreactors
        A cost-effective solution for the current demands of multiple drug pipelines and rapid
                     R&D turnover in the expanding biotherapeutics drug market


 1st - 2nd November 2012, Visiongain Conference Centre, London, UK                        BOOK NOW!


  Key Speakers

  Tim Charlebois, VP Technology and Innovation Strategy, Pfizer


  David Pollard, Associate Director, Merck


  Chetan Goudar, Head Cell Culture Development, Bayer


  Matthew Pietrzykowski, Lead Scientist, GE Healthcare


  Nicolas Fouque, Section Head, Process Development, NovImmune


  Klaus Hermansen, Senior Specialist, NNE Pharmaplan


  Marc Bisschops, Scientific Director, Tarpon Biosystems


  Martina Micheletti, Lecturer, University College London


  Peter Walter, Chief Technology Officer & Principal Consultant, Hyde Engineering and Consulting




                                  Driving the Industry Forward | www.futurepharmaus.com




Media Partners                                                                                     Organised By




       To Book Call: +44 (0) 20 7336 6100 | www.visiongain.com/bioreactors
Conference Introduction
                                                                                                             Single-Use Bioreactors
                                                                                              1st - 2nd November 2012, London, UK

Dear Colleague,                                                                                   Media Partners:
	 the bioreactors market, disposables are one of the fastest growing sectors with the
  In                                                                                                                       PharmiWeb.com is the leading industry-sponsored portal for
  potential for many new breakthroughs and applications in the coming years. They are
  an attractive alternative to the traditional large inflexible stainless steel bioreactors                                the pharmaceutical sector. Supported by most of the leading
  which require substantial capital expenditure. The industry as a whole is experiencing          pharmaceutical corporations, PharmiWeb.com provides dynamic real-time news,
  an increased demand for biologics which requires the use of bioreactors to cultivate            features, events listings and international jobs to industry professionals across Europe
  specific cell lines. The number of clinical monoclonal antibodies (mAbs) in development         and the US.
  is increasing and pharmaceutical companies are looking at developing a diverse                  For further information please email: corporate@pharmiweb.com
  pipeline of mAbs to fill several smaller niches and meet the demand for personalised
  medicine rather than large scale production of blockbusters. This has resulted in the
  industry demanding smaller batch sizes, quicker turnover rates and cheaper production
  costs as budgets are restrained.                                                                                         BIOTECHNOLOGY EUROPE is owned by BIOTECHNOLOGY
	Disposable bioreactors help fill this need as they are fast, flexible and cheap allowing                                 WORLD. It is based and located in Warsaw, Poland.
  for quick experimental runs of new biologics and a scalable platform to a substantial           Biotechnology World was founded in 2007 to provide the world’s biotech and pharma
  size of up to 2000 litres. They are pre-sterilised, thus removing the need for strict
  sterilisation and validation procedures. This process will play an important role for           information and market to make it universally accessible and useful for scientific
  the manufacturing of cheap biosimilars in emerging markets due to a lack of legacy              and business processes. Its first step to fulfilling that mission was building the
  infrastructure and low capital costs. The total market will increase to approximately           BIOTECHNOLOGY EUROPE platform that will allow a quick spread of information in
  $59.1m by 2021, providing ample opportunity for growth.                                         different channels. BIOTECHNOLOGY EUROPE offers companies completed internet
                                                                                                  public relations, publication and marketing solutions. One of the mains goals of
Why you should attend this conference                                                             BIOTECHNOLOGY EUROPE is to integrate the Biotech and Pharma Sector in Europe to
	    • Manage multiple pipelines for niche biotherapeutic products                                global biotechnology, pharmaceutical and life science activities.
	    • Analyse case studies examining ROI and cost/benefit potential                              For further information please visit: www.biotechnology-europe.com
	    • Explore environmentally friendly methods of disposal
	    • Manage a diverse supply chain and increase speed of RD turnaround
	    • Find the right solutions to manage bench to full scale production                                                 Future Pharmaceuticals has forged powerful relationships
                                                                                                         Driving the Industry Forward | www.futurepharmaus.com




	    •  xpand production in rapidly growing BRIC economies with fast implementation and
        E                                                                                                                with key industry leaders to provide a platform for successful
        low capital costs                                                                         brand recognition, and for senior decision-makers to have the means to procure and
	    • Discuss the creation of standardised connectivity across the industry                      plan implementation strategies based on the topics covered. Positioned to be an
	    • Improve downstream processing efficiency and increase capacity                             authoritative resource within top pharma companies as well as small, specialty, and
	    I look forward to meeting you at the conference                                              biotech, Future Pharmaceuticals magazine is geared to create a deep penetration into
                                                                                                  a highly targeted and responsive audience, bridging the gap between the industries’
	    Best regards
                                                                                                  top issues and the solutions top-tier vendors can provide.
                                                                                                  For further information please visit: www.futurepharmaus.com


	 Shahidul Islam                                                                                                       InPharm is the online platform for exclusive pharmaceutical
	 Conference Producer                                                                                                  news, comment, contracts, services, jobs and events and is
                                                                                                  home to InPharmjobs.com, Pharmafile and Pharmafocus.
                                                                                                  For further information please visit: www.inpharm.com


    Who should attend this conference?
    Presidents, Chief Executives, Chief Scientific Officers, Chief
    Operating Officers, Senior Vice Presidents, Vice Presidents, Heads,                           Sponsorship and exhibition opportunities
    Senior Directors, Directors, Clinicians, Principal Scientists, Principal
    Investigators, Managers, Project/Team Leaders in:                                             This event offers a unique opportunity to meet and do business with some
    •	 Bioanalytical Development
    •	 High-Throughput/High-Content Screening Operations
                                                                                                  of the key players in the pharmaceutical and biotech industries. If you have
    •	 Drug Discovery/Validation
                                                                                                  a service or product to promote, you can do so at this event by:
    •	 Health Economics
    •	 Biotherapeutics
                                                                                                  • Hosting a networking drinks reception
    •	 Business and Alliance Development
    •	 Contract Manufacturing and Research Organisations                                          • Taking an exhibition space at the conference
    •	 Drug Safety  Risk Management
    •	 New Product Development                                                                    • Advertising in the delegate documentation pack
    •	 Biosimilars
    •	 Vaccines                                                                                   • Providing branded bags, pens, gifts, etc.
    •	 Bioprocess Engineers
    •	 Drug Delivery                                                                              If you would like more information on the range of sponsorship or
    •	 Lead Generatio
    •	 In Vitro Sciences                                                                          exhibition possibilities for visiongain's Single-Use Bioreactors Conference,
    •	 Pre-clinical Development
    •	 Medicinal Chemistry                                                                        please contact us:
    •	 External/Contract Research
    •	 Global Research and Development                                                            Damian Gorman, +44 (0)20 7549 9934
    •	 Business Development
    •	 Investment and Venture Capital                                                             damian.gorman@visiongainglobal.com
Day 1
                                                                                                                              Single-Use Bioreactors
                                                                                                                        Thursday 1st November 2012

	
    09:00	   Registration and refreshments                                                             13:40	Panel Discussion: What opportunities are there for
                                                                                                              the development of microbial bioreactors and what
                                                                                                              future upstream developments can we expect? Join
    09:30	   Opening address from the Chair                                                                   us for this lively debate with input from industry
                                                                                                              and service providers. Email your questions to
                                                                                                              shahidul.islam@visiongain.com
    09:40	   B
              ioprocess Technology  Innovation: Strategic
             Imperative for Challenging Times
    	        •  hanging landscape of bioprocessing requires new approaches
               C                                                                                       14:20	        Supply chain security for single-use systems
               to production
                                                                                                       	             •  ow to address the inherent risks associated with reliance on
                                                                                                                       H
    	        • Perspective from a large global biopharmaceutical company                                               single-use components
    			 Charlebois
       Tim                                                                                             	             • Develop a supplier management and quality plan
       VP Technology and Innovation Strategy
                                                                                                       			
                                                                                                          Peter Walter
       Pfizer
                                                                                                          Chief Technology Officer  Principal Consultant
                                                                                                          Hyde Engineering and Consulting

    10:20	   D
              esigning a biotech facility for the future with
             single-use technologies                                                                   15:00	        Afternoon Refreshments
    	        • Building a modular facility to enable flexibility and reduce lead time

    	        • Integrating disposable tech with existing pipelines                                     15:20	        Cost/benefit analysis of single-use bioreactors
    			
       Klaus Hermansen
                                                                                                       	             • What is the real enefit of single-use systems?
       Senior Specialist
       NNE Pharmaplan                                                                                  	             • Case-study of a successful implementation and analysis of outcomes

                                                                                                       	             •  hat applications are particularly suited for single-use systems and
                                                                                                                       W
                                                                                                                       which to avoid?
    11:00	   Morning refreshments

                                                                                                       16:00	Upstream process advances and collaborations
    11:20	Will small-scale, high-throughput upstream
                                                                                                              with service providers
           processes become the standard for cell culture
           development?                                                                                	             • The unmet need for microbial bioreactors I disposable systems

    	        • Are small-scale technologies capable of advancing the industry further?                 	             •  ontinous bioprocess using modular disposable systems and
                                                                                                                       C
                                                                                                                       perfusion systems
    	        • Can they continue to reduce costs and increase productivity standards?
                                                                                                       			
                                                                                                          David Pollard
    	        •  uccessful utilisation of multiple small-scale processes to allow access to
               S                                                                                          Merck
               cell line performance information in reduced time

                                                                                                       16:40	        Closing remarks from the Chair
    12:00	   Title to be confirmed
    	        • Engineering bioreactors to solve heat and oxygen transfer issues

    	        • ntegrating intensification technologies into disposables to create
               I
               higher yields
                                                                                                       16:50	Networking drinks
    			
       Martina Micheletti
       Lecturer
                                                                                                       	Take your discussions further and build new
       University College London                                                                          relationships in a relaxed and informal setting


    12:40	   Networking lunch




                     Due to unforeseen circumstances the programme may change and visiongain reserves the right to alter the venue and/or speakers c Copyright visiongain Ltd, 2012
Day 2
                                                                                               Single-Use Bioreactors
                                                                                          Friday 2nd November 2012


09:00	   Registration and refreshments                                   14:20	 be confirmed
                                                                                To
                                                                         	        		atthew Pietrzykowski
                                                                                    M
                                                                                    Lead Scientist
09:30	   Opening address from the chair                                             GE Healthcare



09:40	Case studies of scaling up production using                       15:00	   Afternoon refreshments
       disposable technology
	        • Rapid scale-up of vaccine production using disposables
                                                                         15:20	   K
                                                                                   ey Considerations for Validation of Single Use
	        • Advantages of disposables when time is of the essence
                                                                                  Bioreactors and Risk Management for Leachables
                                                                                  and Extractables
                                                                         	        •  ssessing vendors initially and throughout lifecycle: Audits of Quality
                                                                                    A
10:20	   Accelerating cell culture development
                                                                                    System, Design History and Change Control Procedures, CAPA, and
	        • Future biotherapeutic production plant design                            Supply Chain security.

	        •  argeted cell engineering to reduce variability and create
           T                                                             	        •  electing equipment with construction materials, operating principles, and
                                                                                    S
           stable cell lines                                                        performance characteristics based on whether they are appropriate for
                                                                                    their specific uses.
			
   Chetan Goudar
   Head Cell Culture Development                                         	        •  nalysis of vendor extractables data and material compatibility with
                                                                                    A
   Bayer                                                                            process streams and operating conditions. Applying risk management
                                                                                    principles for assessment of Leachables in a specific process.


11:00	   Morning refreshments
                                                                         16:00	   Downstream processing using disposable systems
                                                                         	        •  urification of biologics in a disposable  setting requires a
                                                                                    P
11:20	   B
          ioSMB™: A Fully Disposable Continuous                                    different approach
         Chromatography for the Purification of                          	        • Existing and emerging platform purification options
         Biopharmaceuticals
                                                                         	        • Solutions to overcome downstream bottlenecks
			Marc Bisschops
			Scientific Director                                                   			
                                                                            Nicolas Fouque
			Tarpon Biosystems                                                        Section Head, Process Development
                                                                            NovImmune


12:00	   Sponsor spotlight
                                                                         16:40	   Chair’s closing remarks


12:40	   Networking lunch
                                                                         16:50	   End of Conference


13:40	Panel Discussion: How can we drive standardisation
       in such a broad market to maintain supply
       chain security? The challenges and proposals for
       standardisation of connectivity. Email your questions
       to shahidul.islam@visiongain.com
Registration Form
                                                                                                                  Single-Use Bioreactors
                                                                                                   1st - 2nd November 2012, London, UK

                                                                                                                                                                                             Angel
                                                                                    Conf. code VG                                                           Pentonville Road


                                                                                                          Single-Use Bioreactors




                                                                                                                                                                                     Ci
                                                                                                                                                                                       ty
Standard Prices




                                                                                                                                                                                         Ro
                                                                                                                                                                                             ad
                                                                                                          1st - 2nd November 2012
Conference only 	                               Fee:	 £1299	   VAT:	 £259.80	   Total:	 £1558.80                                                                                                                  Old Street
                                                                                                          Location: Visiongain Conference Centre
                                                                                                                                                                                Old Street
                                                                                                          Address: 
Number of bookings:				 Total cost:                                                                       230 City Road
                                                                                                          London




                                                                                                                                                                                                      City Road
                                                                                                          EC1V 2TT
                                                                                                          UK
Promotional Literature Distribution
Distribution of your company’s promotional literature to all conference attendees

	                                               Fee:	£999	VAT:	
                                                              £199.80	Total: 	
                                                                             £1198.80                 How to book
                                                                                                      Email: conferences@visiongainglobal.com	
Details                                                                                               Web: http://www.visiongain.com/bioreactors   
                                                                                                      UK Office:
Forename:	                                      Surname:                                              Tel: +44 (0) 20 7336 6100
                                                                                                      Fax: +44 (0) 20 7549 9932	
Job Title:	                                     Company:                                              Visiongain Ltd
                                                                                                      230 City Road
                                                                                                      London
Main Switchboard Number:                                                                              EC1V 2QY
                                                                                                      UK
Address:
                                                                                                      General information
                                                                                                      Venue: Visiongain Conference Centre 230 City Road, London, EC1V 2TT. United Kingdom. Closest tube
                                                                                                      station is Old Street (Northern Line).  Accommodation: Thistle City Barbican, Central Street, Clerkenwell,
                                                                                                      London, EC1V 8DS, Phone: 0871 376 9004 / +44 845 305 8304, Fax: 0871 376 9104 / +44 845 305
                                                                                                      8343, http://www.thistle.com/en/hotels/united_kingdom/london/thistle_city_barbican/index.html
Country:	                                       Postcode:                                             Travelodge London City Road Hotel, 7-12 City Road, London, EC1Y 1AE, Tel: 0871 984 6333, Fax: 0207
                                                                                                      628 2503, http://www.travelodge.co.uk/search_and_book/hotel_overview.php?hotel_id=340
Phone:	                                         Fax:                                                  Payment terms: Visiongain require the full amount to be paid before the conference. Visiongain
                                                                                                      Ltd may refuse entry to delegates who have not paid their invoice in full. A credit card guarantee may
                                                                                                      be requested if payment has not been received in full before the event. Visiongain Ltd reserves the
Email:	                                                                                               right to charge interest on unpaid invoices.
                                                                                                      Substitutions/name changes or cancellations: There is a 50% liability on all bookings once
Signature:                                                                                            made, whether by post, fax, email or web. There is a no refund policy for cancellations received on or
                                                                                                      after one month before the start of the event. Should you decide to cancel after this date, the full invoice
I confirm that I have read and agree to the terms and conditions of booking                           must be paid. Conference notes will then be sent to you. Unfortunately, we are unable to transfer places
                                                                                                      between conferences. However, if you cannot attend the conference, you may make a substitution/
                                                                                                      name change at any time, as long as we are informed in writing by email, fax or post. Name changes
Methods of payment                                                                                    and substitutions must be from the same company or organisation and are not transferable between
                                                                                                      countries. Please note that discounted delegates places at a visiongain event are non refundable.
Payment must be made in sterling
                                                                                                      Invoice alterations: There will be an administration charge of £50 for any changes to an invoice,
	By Mail: Complete and return your signed registration form together with your cheque                excluding substitutions/name changes, requested by the customer. This will be charged to the
                                                                                                      customer by credit card prior to the changes being made.
     payable to Visiongain Ltd and send to: visiongain Ltd, 230 City Road, London, EC1V 2QY, UK       Indemnity: Visiongain Ltd reserves the right to make alterations to the conference/executive
                                                                                                      briefing content, timing, speakers or venue without notice. The event may be postponed or cancelled
	By Fax: Complete and fax your signed registration form with your credit card details                due to unforeseen events beyond the control of visiongain Ltd. If such a situation arises, we will try
     to +44 (0) 20 7549 9932                                                                          to reschedule the event. However, visiongain Ltd cannot be held responsible for any cost, damage or
                                                                                                      expenses, which may be incurred by the customer as a consequence of the event being postponed or
	    By Phone: Call us on +44 (0) 20 7336 6100 with your credit card details                          cancelled. We therefore strongly advise all our conference clients to take out insurance to cover the
                                                                                                      cost of the registration, travel and expenses.
	 Credit Card: Fill in your card details below and fax back to +44 (0) 20 7549 9932
  By                                                                                                  Data Protection: Visiongain Ltd gathers and manages data in accordance with the Data
                                                                                                      Protection Act 1988. Your personal information contained in this form may be used to update you on
	    By Bank Transfer                                                                                 visiongain Ltd products and services via post, telephone, fax or email, unless you state otherwise. We
                                                                                                      may also share your data with external companies offering complementary products or services. If you
	Please debit my credit card:                                                                        wish for your details to be amended, suppressed or not passed on to any external third party, please
                                                                                                      send your request to the Database Manager, visiongain Ltd, BSG House, 226-236 City Road, London,
    Access     MasterCard       Visa     American Express                                             EC1V 2QY. Alternatively, you can visit our website at www.visiongain.com and amend your details.
                                                                                                      Please allow approximately 30 days for your removal or update request to be applied to our database.
                                                                                                      Following your removal or update request, you may receive additional pieces of communication from
                                                                                                      visiongain Ltd during the transitional period, whilst the changes are coming into effect.
Card number:
                                                                                                      Fee: The conference fee includes lunch, refreshments and conference papers provided on the day.
                                                                                                      This fee does not include travel, hotel accommodation, transfers or insurance, (which we strongly
                                                                                                      recommend you obtain).
Expiry Date:                                                                                          VAT: VAT will be charged at the local rate on each conference. TaxPort USA Corp. specializes in
                                                                                                      recovering cross-border VAT. Delegates may be able to recover VAT incurred by contacting TaxPort
Security number (last 3 digits on back of credit card):                                               USA Corp.on: Tel: USA 802.860.0250 or +1.888.298.8296, Europe +41(0)21 310 01 50 or via
                                                                                                      email on: vat@taxport-usa.com, vat@taxport-switzerland.com, vat@taxport-uk.com. For further
                                                                                                      information please check Terms and Conditions on the visiongain.com web site
Signature:
                                                                                                      How we will contact you: Visiongain Ltd’s preferred method of communication is by email and
                                                                                                      phone. Please ensure that you complete the registration form in full so that we can contact you.
Cardholder’s name:
                                                                                                      Unable to attend
                                                                                                      Obviously nothing compares to being there but you need not miss out. Simply tick the box and send
News updates                                                                                          with your payment. You will receive speaker talks in PDFs two weeks after the event.
Please tick if you do not want to receive email news updates in the future                            Yes, please send me speaker talks 	                 Price£550 	       VAT:£110 	               Total:£660




                                                                    www.visiongain.com/bioreactors

Weitere ähnliche Inhalte

Was ist angesagt?

5th Annual Stability Testing (2011) Pp
5th Annual Stability Testing (2011) Pp5th Annual Stability Testing (2011) Pp
5th Annual Stability Testing (2011) PpPiyush Patel
 
5th Lyophilisation (2011) Fb
5th Lyophilisation (2011) Fb5th Lyophilisation (2011) Fb
5th Lyophilisation (2011) FbFateja
 
Clinical Trial Logistics & Supply (2011) Fb
Clinical Trial Logistics & Supply (2011) FbClinical Trial Logistics & Supply (2011) Fb
Clinical Trial Logistics & Supply (2011) FbFateja
 
6th Annual Biosimilars 2010 (Usa)
6th Annual Biosimilars 2010 (Usa)6th Annual Biosimilars 2010 (Usa)
6th Annual Biosimilars 2010 (Usa)gbashe
 
6th Annual Biosimilars 2010 (Usa)
6th Annual Biosimilars 2010 (Usa)6th Annual Biosimilars 2010 (Usa)
6th Annual Biosimilars 2010 (Usa)Coneyskuhl
 
5th Annual Contract Manufacturing (2011) Pp
5th Annual Contract Manufacturing (2011) Pp5th Annual Contract Manufacturing (2011) Pp
5th Annual Contract Manufacturing (2011) PpPiyush Patel
 
11th Annual Biosimilars Uk (2012)
11th Annual Biosimilars Uk (2012)11th Annual Biosimilars Uk (2012)
11th Annual Biosimilars Uk (2012)shad121
 
5th Annual BioManufacturing Asia 2015
5th Annual BioManufacturing Asia 2015 5th Annual BioManufacturing Asia 2015
5th Annual BioManufacturing Asia 2015 Rita Barry
 
Amorphous Pharmaceutical Materials 2010
Amorphous Pharmaceutical Materials 2010Amorphous Pharmaceutical Materials 2010
Amorphous Pharmaceutical Materials 2010Pranita Nangia
 
5th Annual Product Lifecycle Management (2012) Pp
5th Annual Product Lifecycle Management (2012) Pp5th Annual Product Lifecycle Management (2012) Pp
5th Annual Product Lifecycle Management (2012) PpPiyush Patel
 
Biobanking Americas (2010)
Biobanking Americas (2010)Biobanking Americas (2010)
Biobanking Americas (2010)jaayboy69
 
3rd Annual Vaccine Manufacturing (2011) Pp
3rd Annual Vaccine Manufacturing (2011) Pp3rd Annual Vaccine Manufacturing (2011) Pp
3rd Annual Vaccine Manufacturing (2011) PpPiyush Patel
 
7th annual monoclonal antibody (2011)
7th annual monoclonal antibody (2011)7th annual monoclonal antibody (2011)
7th annual monoclonal antibody (2011)Pranita Nangia
 
5th Annual Pharmacovigilance (2010) Ts
5th Annual Pharmacovigilance (2010) Ts5th Annual Pharmacovigilance (2010) Ts
5th Annual Pharmacovigilance (2010) Tstatisalla
 
3rd annual vaccine manufacturing (2011)
3rd annual vaccine manufacturing (2011)3rd annual vaccine manufacturing (2011)
3rd annual vaccine manufacturing (2011)Pranita Nangia
 
Vaccine research & innovation
Vaccine research &  innovationVaccine research &  innovation
Vaccine research & innovationjaayboy69
 
4th Annual Pharmaceutical Plm (2010) Ta
4th Annual Pharmaceutical Plm (2010) Ta4th Annual Pharmaceutical Plm (2010) Ta
4th Annual Pharmaceutical Plm (2010) Tatatisalla
 
Innovation and entrepreneurship in biotechnology an intl perspective - d. h...
Innovation and entrepreneurship in biotechnology   an intl perspective - d. h...Innovation and entrepreneurship in biotechnology   an intl perspective - d. h...
Innovation and entrepreneurship in biotechnology an intl perspective - d. h...sanguru1977
 
3rd Pre Filled Syringes (2010)
3rd Pre Filled Syringes (2010)3rd Pre Filled Syringes (2010)
3rd Pre Filled Syringes (2010)jaayboy69
 

Was ist angesagt? (20)

5th Annual Stability Testing (2011) Pp
5th Annual Stability Testing (2011) Pp5th Annual Stability Testing (2011) Pp
5th Annual Stability Testing (2011) Pp
 
5th Lyophilisation (2011) Fb
5th Lyophilisation (2011) Fb5th Lyophilisation (2011) Fb
5th Lyophilisation (2011) Fb
 
Clinical Trial Logistics & Supply (2011) Fb
Clinical Trial Logistics & Supply (2011) FbClinical Trial Logistics & Supply (2011) Fb
Clinical Trial Logistics & Supply (2011) Fb
 
6th Annual Biosimilars 2010 (Usa)
6th Annual Biosimilars 2010 (Usa)6th Annual Biosimilars 2010 (Usa)
6th Annual Biosimilars 2010 (Usa)
 
6th Annual Biosimilars 2010 (Usa)
6th Annual Biosimilars 2010 (Usa)6th Annual Biosimilars 2010 (Usa)
6th Annual Biosimilars 2010 (Usa)
 
5th Annual Contract Manufacturing (2011) Pp
5th Annual Contract Manufacturing (2011) Pp5th Annual Contract Manufacturing (2011) Pp
5th Annual Contract Manufacturing (2011) Pp
 
11th Annual Biosimilars Uk (2012)
11th Annual Biosimilars Uk (2012)11th Annual Biosimilars Uk (2012)
11th Annual Biosimilars Uk (2012)
 
5th Annual BioManufacturing Asia 2015
5th Annual BioManufacturing Asia 2015 5th Annual BioManufacturing Asia 2015
5th Annual BioManufacturing Asia 2015
 
Amorphous Pharmaceutical Materials 2010
Amorphous Pharmaceutical Materials 2010Amorphous Pharmaceutical Materials 2010
Amorphous Pharmaceutical Materials 2010
 
5th Annual Product Lifecycle Management (2012) Pp
5th Annual Product Lifecycle Management (2012) Pp5th Annual Product Lifecycle Management (2012) Pp
5th Annual Product Lifecycle Management (2012) Pp
 
Biobanking Americas (2010)
Biobanking Americas (2010)Biobanking Americas (2010)
Biobanking Americas (2010)
 
3rd Annual Vaccine Manufacturing (2011) Pp
3rd Annual Vaccine Manufacturing (2011) Pp3rd Annual Vaccine Manufacturing (2011) Pp
3rd Annual Vaccine Manufacturing (2011) Pp
 
7th annual monoclonal antibody (2011)
7th annual monoclonal antibody (2011)7th annual monoclonal antibody (2011)
7th annual monoclonal antibody (2011)
 
5th Annual Pharmacovigilance (2010) Ts
5th Annual Pharmacovigilance (2010) Ts5th Annual Pharmacovigilance (2010) Ts
5th Annual Pharmacovigilance (2010) Ts
 
3rd annual vaccine manufacturing (2011)
3rd annual vaccine manufacturing (2011)3rd annual vaccine manufacturing (2011)
3rd annual vaccine manufacturing (2011)
 
Nano4Health
Nano4HealthNano4Health
Nano4Health
 
Vaccine research & innovation
Vaccine research &  innovationVaccine research &  innovation
Vaccine research & innovation
 
4th Annual Pharmaceutical Plm (2010) Ta
4th Annual Pharmaceutical Plm (2010) Ta4th Annual Pharmaceutical Plm (2010) Ta
4th Annual Pharmaceutical Plm (2010) Ta
 
Innovation and entrepreneurship in biotechnology an intl perspective - d. h...
Innovation and entrepreneurship in biotechnology   an intl perspective - d. h...Innovation and entrepreneurship in biotechnology   an intl perspective - d. h...
Innovation and entrepreneurship in biotechnology an intl perspective - d. h...
 
3rd Pre Filled Syringes (2010)
3rd Pre Filled Syringes (2010)3rd Pre Filled Syringes (2010)
3rd Pre Filled Syringes (2010)
 

Andere mochten auch

Inequations and finding rule
Inequations and finding ruleInequations and finding rule
Inequations and finding ruleamcsquared
 
DID YOU KNOW ?
DID YOU KNOW ?DID YOU KNOW ?
DID YOU KNOW ?IGRIV
 
Plan and create assessments in sa
Plan and create assessments in saPlan and create assessments in sa
Plan and create assessments in saAdam Caplan
 
Trabajo de ofimatica
Trabajo de ofimaticaTrabajo de ofimatica
Trabajo de ofimaticaCRISTO18
 
DC Data Dive - National Environmental Education Foundation
DC Data Dive - National Environmental Education Foundation DC Data Dive - National Environmental Education Foundation
DC Data Dive - National Environmental Education Foundation mayurhpatel
 
Leap pad explorer features 1
Leap pad explorer features 1Leap pad explorer features 1
Leap pad explorer features 1cvhaslacker0
 
KAMBUD Mława
KAMBUD MławaKAMBUD Mława
KAMBUD MławasalonyVi
 
Appalachian Power Wytheville ED Forum - APCo ED Program of Work - John Smolak
Appalachian Power Wytheville ED Forum - APCo ED Program of Work - John SmolakAppalachian Power Wytheville ED Forum - APCo ED Program of Work - John Smolak
Appalachian Power Wytheville ED Forum - APCo ED Program of Work - John SmolakAEP Economic & Business Development
 
Sportal Content Provider
Sportal Content ProviderSportal Content Provider
Sportal Content ProviderMarco Gabbi
 
Мастер-класс в С_Петербурге
Мастер-класс в С_ПетербургеМастер-класс в С_Петербурге
Мастер-класс в С_Петербургеekaterina_a
 
VALMARK Warszawa
VALMARK WarszawaVALMARK Warszawa
VALMARK WarszawasalonyVi
 
THERMEX Lódź
THERMEX LódźTHERMEX Lódź
THERMEX LódźsalonyVi
 
Estefania Acosta Lesson 8 step by step
Estefania Acosta Lesson 8 step by stepEstefania Acosta Lesson 8 step by step
Estefania Acosta Lesson 8 step by stepeacosta007
 

Andere mochten auch (20)

Syaela wati achmad 94
Syaela wati achmad 94Syaela wati achmad 94
Syaela wati achmad 94
 
Raj sekhar envc ppt article 15
Raj sekhar envc ppt article 15Raj sekhar envc ppt article 15
Raj sekhar envc ppt article 15
 
Inequations and finding rule
Inequations and finding ruleInequations and finding rule
Inequations and finding rule
 
DID YOU KNOW ?
DID YOU KNOW ?DID YOU KNOW ?
DID YOU KNOW ?
 
Ibf 8-risk-return
Ibf 8-risk-returnIbf 8-risk-return
Ibf 8-risk-return
 
Plan and create assessments in sa
Plan and create assessments in saPlan and create assessments in sa
Plan and create assessments in sa
 
Trabajo de ofimatica
Trabajo de ofimaticaTrabajo de ofimatica
Trabajo de ofimatica
 
DC Data Dive - National Environmental Education Foundation
DC Data Dive - National Environmental Education Foundation DC Data Dive - National Environmental Education Foundation
DC Data Dive - National Environmental Education Foundation
 
Palace on Wheels - Romancing in Rajasthan
Palace on Wheels - Romancing in RajasthanPalace on Wheels - Romancing in Rajasthan
Palace on Wheels - Romancing in Rajasthan
 
Photography Club(3/22/12)
Photography Club(3/22/12)Photography Club(3/22/12)
Photography Club(3/22/12)
 
2coffee1
2coffee12coffee1
2coffee1
 
Media evaluation
Media evaluationMedia evaluation
Media evaluation
 
Leap pad explorer features 1
Leap pad explorer features 1Leap pad explorer features 1
Leap pad explorer features 1
 
KAMBUD Mława
KAMBUD MławaKAMBUD Mława
KAMBUD Mława
 
Appalachian Power Wytheville ED Forum - APCo ED Program of Work - John Smolak
Appalachian Power Wytheville ED Forum - APCo ED Program of Work - John SmolakAppalachian Power Wytheville ED Forum - APCo ED Program of Work - John Smolak
Appalachian Power Wytheville ED Forum - APCo ED Program of Work - John Smolak
 
Sportal Content Provider
Sportal Content ProviderSportal Content Provider
Sportal Content Provider
 
Мастер-класс в С_Петербурге
Мастер-класс в С_ПетербургеМастер-класс в С_Петербурге
Мастер-класс в С_Петербурге
 
VALMARK Warszawa
VALMARK WarszawaVALMARK Warszawa
VALMARK Warszawa
 
THERMEX Lódź
THERMEX LódźTHERMEX Lódź
THERMEX Lódź
 
Estefania Acosta Lesson 8 step by step
Estefania Acosta Lesson 8 step by stepEstefania Acosta Lesson 8 step by step
Estefania Acosta Lesson 8 step by step
 

Ähnlich wie Single Use Bioreactors (2012)

Biobanking 2010 Ta
Biobanking 2010 TaBiobanking 2010 Ta
Biobanking 2010 Tatatisalla
 
Biobanking americas (2011)
Biobanking americas (2011)Biobanking americas (2011)
Biobanking americas (2011)Pranita Nangia
 
Aesthetics and anti ageing (2011)
Aesthetics and anti ageing (2011)Aesthetics and anti ageing (2011)
Aesthetics and anti ageing (2011)Pranita Nangia
 
9th Annual Pricing And Reimbursement Conference
9th Annual Pricing And Reimbursement Conference9th Annual Pricing And Reimbursement Conference
9th Annual Pricing And Reimbursement Conferencejaayboy69
 
10th Annual Pricing & Reimbursement (2011) Pp
10th Annual Pricing & Reimbursement (2011) Pp10th Annual Pricing & Reimbursement (2011) Pp
10th Annual Pricing & Reimbursement (2011) PpPiyush Patel
 
Gpcr & Kinase Targets (2011) Pp
Gpcr & Kinase Targets (2011) PpGpcr & Kinase Targets (2011) Pp
Gpcr & Kinase Targets (2011) PpKarnika Dawar
 
Anti Counterfeiting Americas (2010)
Anti Counterfeiting Americas (2010)Anti Counterfeiting Americas (2010)
Anti Counterfeiting Americas (2010)jaayboy69
 
6th annual pharmacovigilance conference (2011)
6th annual pharmacovigilance conference (2011)6th annual pharmacovigilance conference (2011)
6th annual pharmacovigilance conference (2011)Pranita Nangia
 
BioSimilar Drug Development World
BioSimilar Drug Development WorldBioSimilar Drug Development World
BioSimilar Drug Development WorldGeneric Pharma 2.0
 
7th Annual Pharmacovigilance (2012) Pp
7th Annual Pharmacovigilance (2012) Pp7th Annual Pharmacovigilance (2012) Pp
7th Annual Pharmacovigilance (2012) PpPiyush Patel
 
9th Biosimilars Conference Brochure
9th Biosimilars Conference   Brochure9th Biosimilars Conference   Brochure
9th Biosimilars Conference Brochuresandy_nguyen
 
Pfizer, GE Healthcare, Novartis Pharma and Boehringer-Ingelheim Pharma Confir...
Pfizer, GE Healthcare, Novartis Pharma and Boehringer-Ingelheim Pharma Confir...Pfizer, GE Healthcare, Novartis Pharma and Boehringer-Ingelheim Pharma Confir...
Pfizer, GE Healthcare, Novartis Pharma and Boehringer-Ingelheim Pharma Confir...Torben Haagh
 
Cns clinical trials (2010)
Cns clinical trials (2010)Cns clinical trials (2010)
Cns clinical trials (2010)jaayboy69
 
9th Biosimilars (2011) Pp
9th Biosimilars (2011) Pp9th Biosimilars (2011) Pp
9th Biosimilars (2011) PpPiyush Patel
 

Ähnlich wie Single Use Bioreactors (2012) (16)

Biobanking 2010 Ta
Biobanking 2010 TaBiobanking 2010 Ta
Biobanking 2010 Ta
 
Biobanking americas (2011)
Biobanking americas (2011)Biobanking americas (2011)
Biobanking americas (2011)
 
Aesthetics and anti ageing (2011)
Aesthetics and anti ageing (2011)Aesthetics and anti ageing (2011)
Aesthetics and anti ageing (2011)
 
9th Annual Pricing And Reimbursement Conference
9th Annual Pricing And Reimbursement Conference9th Annual Pricing And Reimbursement Conference
9th Annual Pricing And Reimbursement Conference
 
10th Annual Pricing & Reimbursement (2011) Pp
10th Annual Pricing & Reimbursement (2011) Pp10th Annual Pricing & Reimbursement (2011) Pp
10th Annual Pricing & Reimbursement (2011) Pp
 
Gpcr & Kinase Targets (2011) Pp
Gpcr & Kinase Targets (2011) PpGpcr & Kinase Targets (2011) Pp
Gpcr & Kinase Targets (2011) Pp
 
8th biosimilars congregation 2016
8th biosimilars congregation 20168th biosimilars congregation 2016
8th biosimilars congregation 2016
 
8th biosimilars congregation 2016
8th biosimilars congregation 20168th biosimilars congregation 2016
8th biosimilars congregation 2016
 
Anti Counterfeiting Americas (2010)
Anti Counterfeiting Americas (2010)Anti Counterfeiting Americas (2010)
Anti Counterfeiting Americas (2010)
 
6th annual pharmacovigilance conference (2011)
6th annual pharmacovigilance conference (2011)6th annual pharmacovigilance conference (2011)
6th annual pharmacovigilance conference (2011)
 
BioSimilar Drug Development World
BioSimilar Drug Development WorldBioSimilar Drug Development World
BioSimilar Drug Development World
 
7th Annual Pharmacovigilance (2012) Pp
7th Annual Pharmacovigilance (2012) Pp7th Annual Pharmacovigilance (2012) Pp
7th Annual Pharmacovigilance (2012) Pp
 
9th Biosimilars Conference Brochure
9th Biosimilars Conference   Brochure9th Biosimilars Conference   Brochure
9th Biosimilars Conference Brochure
 
Pfizer, GE Healthcare, Novartis Pharma and Boehringer-Ingelheim Pharma Confir...
Pfizer, GE Healthcare, Novartis Pharma and Boehringer-Ingelheim Pharma Confir...Pfizer, GE Healthcare, Novartis Pharma and Boehringer-Ingelheim Pharma Confir...
Pfizer, GE Healthcare, Novartis Pharma and Boehringer-Ingelheim Pharma Confir...
 
Cns clinical trials (2010)
Cns clinical trials (2010)Cns clinical trials (2010)
Cns clinical trials (2010)
 
9th Biosimilars (2011) Pp
9th Biosimilars (2011) Pp9th Biosimilars (2011) Pp
9th Biosimilars (2011) Pp
 

Single Use Bioreactors (2012)

  • 1. Single-Use Bioreactors A cost-effective solution for the current demands of multiple drug pipelines and rapid R&D turnover in the expanding biotherapeutics drug market 1st - 2nd November 2012, Visiongain Conference Centre, London, UK BOOK NOW! Key Speakers Tim Charlebois, VP Technology and Innovation Strategy, Pfizer David Pollard, Associate Director, Merck Chetan Goudar, Head Cell Culture Development, Bayer Matthew Pietrzykowski, Lead Scientist, GE Healthcare Nicolas Fouque, Section Head, Process Development, NovImmune Klaus Hermansen, Senior Specialist, NNE Pharmaplan Marc Bisschops, Scientific Director, Tarpon Biosystems Martina Micheletti, Lecturer, University College London Peter Walter, Chief Technology Officer & Principal Consultant, Hyde Engineering and Consulting Driving the Industry Forward | www.futurepharmaus.com Media Partners Organised By To Book Call: +44 (0) 20 7336 6100 | www.visiongain.com/bioreactors
  • 2. Conference Introduction Single-Use Bioreactors 1st - 2nd November 2012, London, UK Dear Colleague, Media Partners: the bioreactors market, disposables are one of the fastest growing sectors with the In PharmiWeb.com is the leading industry-sponsored portal for potential for many new breakthroughs and applications in the coming years. They are an attractive alternative to the traditional large inflexible stainless steel bioreactors the pharmaceutical sector. Supported by most of the leading which require substantial capital expenditure. The industry as a whole is experiencing pharmaceutical corporations, PharmiWeb.com provides dynamic real-time news, an increased demand for biologics which requires the use of bioreactors to cultivate features, events listings and international jobs to industry professionals across Europe specific cell lines. The number of clinical monoclonal antibodies (mAbs) in development and the US. is increasing and pharmaceutical companies are looking at developing a diverse For further information please email: corporate@pharmiweb.com pipeline of mAbs to fill several smaller niches and meet the demand for personalised medicine rather than large scale production of blockbusters. This has resulted in the industry demanding smaller batch sizes, quicker turnover rates and cheaper production costs as budgets are restrained. BIOTECHNOLOGY EUROPE is owned by BIOTECHNOLOGY Disposable bioreactors help fill this need as they are fast, flexible and cheap allowing WORLD. It is based and located in Warsaw, Poland. for quick experimental runs of new biologics and a scalable platform to a substantial Biotechnology World was founded in 2007 to provide the world’s biotech and pharma size of up to 2000 litres. They are pre-sterilised, thus removing the need for strict sterilisation and validation procedures. This process will play an important role for information and market to make it universally accessible and useful for scientific the manufacturing of cheap biosimilars in emerging markets due to a lack of legacy and business processes. Its first step to fulfilling that mission was building the infrastructure and low capital costs. The total market will increase to approximately BIOTECHNOLOGY EUROPE platform that will allow a quick spread of information in $59.1m by 2021, providing ample opportunity for growth. different channels. BIOTECHNOLOGY EUROPE offers companies completed internet public relations, publication and marketing solutions. One of the mains goals of Why you should attend this conference BIOTECHNOLOGY EUROPE is to integrate the Biotech and Pharma Sector in Europe to • Manage multiple pipelines for niche biotherapeutic products global biotechnology, pharmaceutical and life science activities. • Analyse case studies examining ROI and cost/benefit potential For further information please visit: www.biotechnology-europe.com • Explore environmentally friendly methods of disposal • Manage a diverse supply chain and increase speed of RD turnaround • Find the right solutions to manage bench to full scale production Future Pharmaceuticals has forged powerful relationships Driving the Industry Forward | www.futurepharmaus.com • xpand production in rapidly growing BRIC economies with fast implementation and E with key industry leaders to provide a platform for successful low capital costs brand recognition, and for senior decision-makers to have the means to procure and • Discuss the creation of standardised connectivity across the industry plan implementation strategies based on the topics covered. Positioned to be an • Improve downstream processing efficiency and increase capacity authoritative resource within top pharma companies as well as small, specialty, and I look forward to meeting you at the conference biotech, Future Pharmaceuticals magazine is geared to create a deep penetration into a highly targeted and responsive audience, bridging the gap between the industries’ Best regards top issues and the solutions top-tier vendors can provide. For further information please visit: www.futurepharmaus.com Shahidul Islam InPharm is the online platform for exclusive pharmaceutical Conference Producer news, comment, contracts, services, jobs and events and is home to InPharmjobs.com, Pharmafile and Pharmafocus. For further information please visit: www.inpharm.com Who should attend this conference? Presidents, Chief Executives, Chief Scientific Officers, Chief Operating Officers, Senior Vice Presidents, Vice Presidents, Heads, Sponsorship and exhibition opportunities Senior Directors, Directors, Clinicians, Principal Scientists, Principal Investigators, Managers, Project/Team Leaders in: This event offers a unique opportunity to meet and do business with some • Bioanalytical Development • High-Throughput/High-Content Screening Operations of the key players in the pharmaceutical and biotech industries. If you have • Drug Discovery/Validation a service or product to promote, you can do so at this event by: • Health Economics • Biotherapeutics • Hosting a networking drinks reception • Business and Alliance Development • Contract Manufacturing and Research Organisations • Taking an exhibition space at the conference • Drug Safety Risk Management • New Product Development • Advertising in the delegate documentation pack • Biosimilars • Vaccines • Providing branded bags, pens, gifts, etc. • Bioprocess Engineers • Drug Delivery If you would like more information on the range of sponsorship or • Lead Generatio • In Vitro Sciences exhibition possibilities for visiongain's Single-Use Bioreactors Conference, • Pre-clinical Development • Medicinal Chemistry please contact us: • External/Contract Research • Global Research and Development Damian Gorman, +44 (0)20 7549 9934 • Business Development • Investment and Venture Capital damian.gorman@visiongainglobal.com
  • 3. Day 1 Single-Use Bioreactors Thursday 1st November 2012 09:00 Registration and refreshments 13:40 Panel Discussion: What opportunities are there for the development of microbial bioreactors and what future upstream developments can we expect? Join 09:30 Opening address from the Chair us for this lively debate with input from industry and service providers. Email your questions to shahidul.islam@visiongain.com 09:40 B ioprocess Technology Innovation: Strategic Imperative for Challenging Times • hanging landscape of bioprocessing requires new approaches C 14:20 Supply chain security for single-use systems to production • ow to address the inherent risks associated with reliance on H • Perspective from a large global biopharmaceutical company single-use components Charlebois Tim • Develop a supplier management and quality plan VP Technology and Innovation Strategy Peter Walter Pfizer Chief Technology Officer Principal Consultant Hyde Engineering and Consulting 10:20 D esigning a biotech facility for the future with single-use technologies 15:00 Afternoon Refreshments • Building a modular facility to enable flexibility and reduce lead time • Integrating disposable tech with existing pipelines 15:20 Cost/benefit analysis of single-use bioreactors Klaus Hermansen • What is the real enefit of single-use systems? Senior Specialist NNE Pharmaplan • Case-study of a successful implementation and analysis of outcomes • hat applications are particularly suited for single-use systems and W which to avoid? 11:00 Morning refreshments 16:00 Upstream process advances and collaborations 11:20 Will small-scale, high-throughput upstream with service providers processes become the standard for cell culture development? • The unmet need for microbial bioreactors I disposable systems • Are small-scale technologies capable of advancing the industry further? • ontinous bioprocess using modular disposable systems and C perfusion systems • Can they continue to reduce costs and increase productivity standards? David Pollard • uccessful utilisation of multiple small-scale processes to allow access to S Merck cell line performance information in reduced time 16:40 Closing remarks from the Chair 12:00 Title to be confirmed • Engineering bioreactors to solve heat and oxygen transfer issues • ntegrating intensification technologies into disposables to create I higher yields 16:50 Networking drinks Martina Micheletti Lecturer Take your discussions further and build new University College London relationships in a relaxed and informal setting 12:40 Networking lunch Due to unforeseen circumstances the programme may change and visiongain reserves the right to alter the venue and/or speakers c Copyright visiongain Ltd, 2012
  • 4. Day 2 Single-Use Bioreactors Friday 2nd November 2012 09:00 Registration and refreshments 14:20 be confirmed To atthew Pietrzykowski M Lead Scientist 09:30 Opening address from the chair GE Healthcare 09:40 Case studies of scaling up production using 15:00 Afternoon refreshments disposable technology • Rapid scale-up of vaccine production using disposables 15:20 K ey Considerations for Validation of Single Use • Advantages of disposables when time is of the essence Bioreactors and Risk Management for Leachables and Extractables • ssessing vendors initially and throughout lifecycle: Audits of Quality A 10:20 Accelerating cell culture development System, Design History and Change Control Procedures, CAPA, and • Future biotherapeutic production plant design Supply Chain security. • argeted cell engineering to reduce variability and create T • electing equipment with construction materials, operating principles, and S stable cell lines performance characteristics based on whether they are appropriate for their specific uses. Chetan Goudar Head Cell Culture Development • nalysis of vendor extractables data and material compatibility with A Bayer process streams and operating conditions. Applying risk management principles for assessment of Leachables in a specific process. 11:00 Morning refreshments 16:00 Downstream processing using disposable systems • urification of biologics in a disposable setting requires a P 11:20 B ioSMB™: A Fully Disposable Continuous different approach Chromatography for the Purification of • Existing and emerging platform purification options Biopharmaceuticals • Solutions to overcome downstream bottlenecks Marc Bisschops Scientific Director Nicolas Fouque Tarpon Biosystems Section Head, Process Development NovImmune 12:00 Sponsor spotlight 16:40 Chair’s closing remarks 12:40 Networking lunch 16:50 End of Conference 13:40 Panel Discussion: How can we drive standardisation in such a broad market to maintain supply chain security? The challenges and proposals for standardisation of connectivity. Email your questions to shahidul.islam@visiongain.com
  • 5. Registration Form Single-Use Bioreactors 1st - 2nd November 2012, London, UK Angel Conf. code VG Pentonville Road Single-Use Bioreactors Ci ty Standard Prices Ro ad 1st - 2nd November 2012 Conference only Fee: £1299 VAT: £259.80 Total: £1558.80 Old Street Location: Visiongain Conference Centre Old Street Address: Number of bookings: Total cost: 230 City Road London City Road EC1V 2TT UK Promotional Literature Distribution Distribution of your company’s promotional literature to all conference attendees Fee: £999 VAT: £199.80 Total: £1198.80 How to book Email: conferences@visiongainglobal.com Details Web: http://www.visiongain.com/bioreactors UK Office: Forename: Surname: Tel: +44 (0) 20 7336 6100 Fax: +44 (0) 20 7549 9932 Job Title: Company: Visiongain Ltd 230 City Road London Main Switchboard Number: EC1V 2QY UK Address: General information Venue: Visiongain Conference Centre 230 City Road, London, EC1V 2TT. United Kingdom. Closest tube station is Old Street (Northern Line). Accommodation: Thistle City Barbican, Central Street, Clerkenwell, London, EC1V 8DS, Phone: 0871 376 9004 / +44 845 305 8304, Fax: 0871 376 9104 / +44 845 305 8343, http://www.thistle.com/en/hotels/united_kingdom/london/thistle_city_barbican/index.html Country: Postcode: Travelodge London City Road Hotel, 7-12 City Road, London, EC1Y 1AE, Tel: 0871 984 6333, Fax: 0207 628 2503, http://www.travelodge.co.uk/search_and_book/hotel_overview.php?hotel_id=340 Phone: Fax: Payment terms: Visiongain require the full amount to be paid before the conference. Visiongain Ltd may refuse entry to delegates who have not paid their invoice in full. A credit card guarantee may be requested if payment has not been received in full before the event. Visiongain Ltd reserves the Email: right to charge interest on unpaid invoices. Substitutions/name changes or cancellations: There is a 50% liability on all bookings once Signature: made, whether by post, fax, email or web. There is a no refund policy for cancellations received on or after one month before the start of the event. Should you decide to cancel after this date, the full invoice I confirm that I have read and agree to the terms and conditions of booking must be paid. Conference notes will then be sent to you. Unfortunately, we are unable to transfer places between conferences. However, if you cannot attend the conference, you may make a substitution/ name change at any time, as long as we are informed in writing by email, fax or post. Name changes Methods of payment and substitutions must be from the same company or organisation and are not transferable between countries. Please note that discounted delegates places at a visiongain event are non refundable. Payment must be made in sterling Invoice alterations: There will be an administration charge of £50 for any changes to an invoice, By Mail: Complete and return your signed registration form together with your cheque excluding substitutions/name changes, requested by the customer. This will be charged to the customer by credit card prior to the changes being made. payable to Visiongain Ltd and send to: visiongain Ltd, 230 City Road, London, EC1V 2QY, UK Indemnity: Visiongain Ltd reserves the right to make alterations to the conference/executive briefing content, timing, speakers or venue without notice. The event may be postponed or cancelled By Fax: Complete and fax your signed registration form with your credit card details due to unforeseen events beyond the control of visiongain Ltd. If such a situation arises, we will try to +44 (0) 20 7549 9932 to reschedule the event. However, visiongain Ltd cannot be held responsible for any cost, damage or expenses, which may be incurred by the customer as a consequence of the event being postponed or By Phone: Call us on +44 (0) 20 7336 6100 with your credit card details cancelled. We therefore strongly advise all our conference clients to take out insurance to cover the cost of the registration, travel and expenses. Credit Card: Fill in your card details below and fax back to +44 (0) 20 7549 9932 By Data Protection: Visiongain Ltd gathers and manages data in accordance with the Data Protection Act 1988. Your personal information contained in this form may be used to update you on By Bank Transfer visiongain Ltd products and services via post, telephone, fax or email, unless you state otherwise. We may also share your data with external companies offering complementary products or services. If you Please debit my credit card: wish for your details to be amended, suppressed or not passed on to any external third party, please send your request to the Database Manager, visiongain Ltd, BSG House, 226-236 City Road, London, Access MasterCard Visa American Express EC1V 2QY. Alternatively, you can visit our website at www.visiongain.com and amend your details. Please allow approximately 30 days for your removal or update request to be applied to our database. Following your removal or update request, you may receive additional pieces of communication from visiongain Ltd during the transitional period, whilst the changes are coming into effect. Card number: Fee: The conference fee includes lunch, refreshments and conference papers provided on the day. This fee does not include travel, hotel accommodation, transfers or insurance, (which we strongly recommend you obtain). Expiry Date: VAT: VAT will be charged at the local rate on each conference. TaxPort USA Corp. specializes in recovering cross-border VAT. Delegates may be able to recover VAT incurred by contacting TaxPort Security number (last 3 digits on back of credit card): USA Corp.on: Tel: USA 802.860.0250 or +1.888.298.8296, Europe +41(0)21 310 01 50 or via email on: vat@taxport-usa.com, vat@taxport-switzerland.com, vat@taxport-uk.com. For further information please check Terms and Conditions on the visiongain.com web site Signature: How we will contact you: Visiongain Ltd’s preferred method of communication is by email and phone. Please ensure that you complete the registration form in full so that we can contact you. Cardholder’s name: Unable to attend Obviously nothing compares to being there but you need not miss out. Simply tick the box and send News updates with your payment. You will receive speaker talks in PDFs two weeks after the event. Please tick if you do not want to receive email news updates in the future Yes, please send me speaker talks Price£550 VAT:£110 Total:£660 www.visiongain.com/bioreactors